Isomorphic Labs, a subsidiary of Alphabet Inc., is trying to use artificial intelligence to understand biology and transform the way new medicines are discovered and developed. Bloomberg’s Tom Mackenzie spoke exclusively with the company’s Chief AI Officer Max Jaderberg and its Head of Medicinal Drug Design Rebecca Paul about the technology behind their drug design engine and how it could reshape the future of healthcare, potentially turning cancer in a chronic, but livable disease.
Chapters:
00:00:00 – Isomorphic Labs building drug design engine
00:03:52 – AlphaFold breakthroughs
00:06:26 – How do we design these molecules?
00:08:22 – Data integrity in building AI tools for drug discovery
00:09:48 – Generalizability is key
00:12:08 – Why focus on immunology and oncology
00:16:15 – Novartis and Eli Lilly partnership
00:17:09 – Curing cancer
00:19:01 – Future of medicine
——–
Like this video? Subscribe to Bloomberg Technology on YouTube:
Watch the latest full episodes of “Bloomberg Technology” with Caroline Hyde and Ed Ludlow here:
Get the latest in tech from Silicon Valley and around the world here:
Connect with us on…
X:
Facebook:
Instagram:
Follow Ed Ludlow on X here:
Follow Caroline Hyde on X here:
Listen to the daily Bloomberg Technology podcast here:
More from Bloomberg Business
Connect with us on…
X:
Facebook:
Instagram:
LinkedIn:
TikTok:
source
